Antithrombotic therapy for stroke prevention in atrial fibrillation.

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation.

PURPOSE To characterize the efficacy and safety of anticoagulants and antiplatelet agents for prevention of stroke in patients with atrial fibrillation. DATA SOURCES Randomized trials identified by using the search strategy developed by the Cochrane Collaboration Stroke Review Group. STUDY SELECTION All published randomized trials testing antithrombotic agents to prevent stroke in patients ...

Termination of anticoagulation therapy at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion resulting in device-related thrombosis and stroke

Catheter ablation therapy for atrial fibrillation (AF) is a safe and effective treatment for patients with both paroxysmal and persistent symptomatic AF. However, given the uncertainty about recurrence after the ablation procedure and continued risk of thromboembolism, it is still recommended to treat with anticoagulation for the long-term prevention of stroke. Left atrial appendage (LAA) occlu...

Randomized Controlled Trial Therapy for Stroke Prevention in Atrial Fibrillation: A A Patient Decision Aid Regarding Antithrombotic

Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation.

Atrial Fibrillation (AF) is the most common clinically significant sustained cardiac arrhythmia, a major risk factor for strokes whether it is symptomatic or silent. The older CHADS2 score and the newer CHADS2-VASc are well validated to determine stroke risk and guide initiation of antithrombotic therapy, but haemorrhagic risk has to be respected as well, and scores such as HAS-BLED should be w...

Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.

BACKGROUND AND PURPOSE Warfarin is the most effective stroke prevention medication for high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the magnitude of this problem in a large contemporary, prospective stroke registry. METHODS We analyzed data from the Registry of the Canadian Stroke Network, a prospective database of consecutive patients with st...

Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial.

BACKGROUND AND PURPOSE Transient ischemic attacks (TIAs) are infrequent in patients with atrial fibrillation, and little is known about the long-term prognosis and response to antithrombotic therapy. METHODS This study was a pooled analysis of participants in 2 randomized trials, the European Atrial Fibrillation Trial and the Stroke Prevention in Atrial Fibrillation III Trial, comparing those...